Products
CE Global Private Equity offers a wide range of investment products and services for retail and corporate investors.
Investment Performance Case Study
Firebrick Pharma Ltd
Welcome to the Investment Performance Case Study of Firebrick Pharma Ltd, which follows our clients' journeys of investing in Firebrick Pharma Ltd between 28th Jan, 2022 and 31st Jan, 2022, during which the recorded share price produced a gain of 275%.
ASX:FRE
Introduction
Firebrick Pharma is a pharmaceutical company developing and commercializing novel formulations of povidone-iodine, including Nasodine Nasal Spray.
The Firebrick Pharma Ltd Investment Case
Firebrick Pharma is an Australian pharmaceutical company established to develop and commercialise novel pharmaceutical products. Its ASX listing provided the company with access to public-market capital to support the continued development and commercialisation of its product portfolio.
The Transaction
Firebrick Pharma commenced trading on the Australian Securities Exchange on 28 January 2022 following an initial public offering at A$0.20 per share.
Investment Outcome
The study records an outcome price of A$0.75 by 31 January 2022. This represented an increase of approximately 275% against the IPO price over the company's opening period of public trading.
- Event: Initial Public Offering
- Exchange: Australian Securities Exchange
- Study Period: 28 January 2022 – 31 January 2022
- Entry Price: A$0.20
- Outcome Price: A$0.75
Case Overview
| Company Name : | Firebrick Pharma Ltd |
|---|---|
| Sector : | Pharmaceutical |
| Event Type : | IPO |
| Buy Advice : | 2022-01-28 |
| Sell Advice : | 2022-01-31 |
| Buy Price : | 0.20 (AUD) |
| Sell Price : | 0.75 (AUD) |
| Profit(%) : | 275% |
Case Studies
Related Studies
Jin Medical International Ltd.
The case study of the Jin Medical International Ltd. IPO in 2024
Oxford Nanopore Technologies
The case study of the Oxford Nanopore Technologies IPO in 2021
